+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sustained Release Excipients Market Size, Share & Trends Analysis Report By Product (Polymers, Gelatin), By Route of Administration (Oral, Transdermal), By Technology (Targeted Delivery), And Segment Forecasts, 2018 - 2026

  • ID: 4661543
  • Report
  • September 2018
  • Region: Global
  • 147 pages
  • Grand View Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Alkermes plc
  • Aradigm Corporation
  • Capsugel
  • Depomed, Inc.
  • Mylan N.V.
  • Orbis Biosciences, Inc.
  • MORE
The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the forecast period. Increasing focus on novel drug delivery R&D and rising adoption of extended release formulations for treatment of chronic diseases are major factors driving the market.

Use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits. Reduced dosage frequency, improved patient compliance, maintenance of constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness in the long run are some of the major advantages of using this technology.

Global rise in incidence of chronic and infectious diseases has also resulted in antibiotic resistance, which negatively affects the market for conventional dosage forms. Thus, alternative methods to manage and treat these diseases are being implemented. Use of sustained release formulations has been widely accepted among physicians in order to combat antibiotic resistance. Since these formulations create desired therapeutic drug levels in blood plasma and reduce dosage frequency, they are the preferred choice of formulation among physicians, which increases their demand.

Further key findings from the report suggest:
  • Polymers formed the largest revenue grossing segment by product type in 2017 and is anticipated to grow at a lucrative rate during the forecast period. This is due to its high adoption in sustained release formulations as they provide greater strength and improved shelf-life
  • In terms of route of administration, the oral segment held the dominant share in 2017 and is projected to witness steady growth to retain its lead throughout the forecast period
  • Transdermal technology is expected to exhibit the highest CAGR during the forecast period owing to its escalating usage. It minimizes various limitations associated with oral and parenteral route of administrations
  • North America dominated the overall market in 2017 due to well-developed research infrastructure and presence of leading pharmaceutical and biopharmaceutical companies
  • Asia Pacific is spearheading revenue growth, with Japan, China, and India at the forefront
  • Some of the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium International, Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.; and Alkermes plc.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alkermes plc
  • Aradigm Corporation
  • Capsugel
  • Depomed, Inc.
  • Mylan N.V.
  • Orbis Biosciences, Inc.
  • MORE

Chapter 1 Executive Summary

Chapter 2 Research Methodology
2.1 Country-wise Market: Base Estimates
2.2 Global Market: CAGR Calculation
2.3 Region-based Segment Share Calculation
2.4 Research Scope & Assumptions
2.5 List of Data Sources
2.5.1 Data for primary interviews, by sources
2.5.2 Data for primary interviews, by region
2.6 Market Snapshot

Chapter 3 Sustained Release Excipients Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increased benefits over conventional dosage forms
3.2.2 Antibiotic resistance
3.2.3 Necessity of pediatric and geriatric sustained release dosage forms
3.2.4 Increased acceptance due to nature of dosage forms
3.3 Market Restraint Analysis
3.3.1 Drug toxicity due to dose dumping
3.3.2 Need for high dose of API
3.4 Market Challenge Analysis
3.4.1 Patient education and counselling
3.4.2 Higher cost of sustained release systems in comparison to conventional pharmaceutical formulations
3.5 Market Opportunity Analysis
3.5.1 Development cost-efficient dosage forms
3.5.2 Minimization of hepatic first pass elimination
3.6 Market Opportunity Analysis
3.6.1 Key opportunities prioritized, by product
3.6.2 Key opportunities prioritized, by route of administration
3.6.3 Key opportunities prioritized, by technology
3.7 Sustained Release Excipients - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.8 Industry Analysis - Porter’s
3.9 Major Excipients Used in Sustained Release Formulations

Chapter 4 Sustained Release Excipients Market: Product Estimates & Trend Analysis
4.1 Sustained Release Excipients Market: Product Movement Analysis
4.2 Gelatin
4.2.1 Gelatin market, 2015 - 2026 (USD Million)
4.3 Polymers
4.3.1 Polymers market, 2015 - 2026 (USD Million)
4.4 Minerals
4.4.1 Minerals market, 2015 - 2026 (USD Million)
4.5 Sugars
4.5.1 Sugars market, 2015 - 2026 (USD Million)
4.6 Alcohol
4.6.1 Alcohol market, 2015 - 2026 (USD Million)
4.7 Chitosan
4.7.1 Chitosan market, 2015 - 2026 (USD Million)

Chapter 5 Sustained Release Excipients Market: Route of Administration Estimates & Trend Analysis
5.1 Sustained release excipients market: Route of administration movement analysis
5.2 Oral
5.2.1 Oral market, 2015 - 2026 (USD Million)
5.3 Intramuscular
5.3.1 Intramuscular market, 2015 - 2026 (USD Million)
5.4 Subcutaneous
5.4.1 Subcutaneous market, 2015 - 2026 (USD Million)
5.5 Transdermal
5.5.1 Transdermal market, 2015 - 2026 (USD Million)
5.6 Vaginal
5.6.1 Vaginal market, 2015 - 2026 (USD Million)
5.7 Ophthalmic
5.7.1 Ophthalmic market, 2015 - 2026 (USD Million)
5.8 Intravenous
5.8.1 Intravenous market, 2015 - 2026 (USD Million)
5.9 Others
5.9.1 Others market, 2015 - 2026 (USD Million)

Chapter 6 Sustained Release Excipients Market: Technology Estimates & Trend Analysis
6.1 Sustained release excipients market: Technology movement analysis
6.2 Targeted Delivery
6.2.1 Targeted delivery market, 2015 - 2026 (USD Million)
6.3 Microencapsulation
6.3.1 Micro encapsulation market, 2015 - 2026 (USD Million)
6.4 Wurster Technique
6.4.1 Wurster technique market, 2015 - 2026 (USD Million)
6.5 Transdermal
6.5.1 Transdermal market, 2015 - 2026 (USD Million)
6.6 Implants
6.6.1 Implants market, 2015 - 2026 (USD Million)
6.7 Coacervation
6.7.1 Coacervation market, 2015 - 2026 (USD Million)
6.8 Others
6.8.1 Others market, 2015 - 2026 (USD Million)

Chapter 7 Sustained Release Excipients Market: Regional Estimates & Trend Analysis, by Product, Route of Administration, and Technology
7.1 Sustained release excipients market share by region, 2017 & 2026
7.2 North America
7.2.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.2.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.2.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.2.4 U.S.
7.2.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.2.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.2.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.2.5 Canada
7.2.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.2.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.2.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.3 Europe
7.3.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.3.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.3.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.3.4 Germany
7.3.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.3.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.3.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.3.5 U.K.
7.3.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.3.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.3.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4 Asia Pacific
7.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4.4 Japan
7.4.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4.5 China
7.4.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4.6 India
7.4.6.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.6.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.6.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.5 Latin America
7.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.5.4 Brazil
7.5.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.5.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.5.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.5.5 Mexico
7.5.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.5.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.5.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.6.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.6.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.6.4 South Africa
7.6.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.6.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.6.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)

Chapter 8 Competitive Landscape: Sustained Release Drugs
8.1 Teva Pharmaceutical Industries Ltd.
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 Mylan N.V.
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Valeant Pharmaceuticals International, Inc.
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 Pfizer, Inc.
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 Sun Pharmaceutical Industries Ltd.
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Novartis AG
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 AstraZeneca
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 GlaxoSmithKline plc
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.9 Allergan plc
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Janssen Pharmaceuticals, Inc.
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
8.11 Mayne Pharma Group Limited
8.11.1 Company overview
8.11.2 Financial performance
8.11.3 Product benchmarking
8.11.4 Strategic initiatives

Chapter 9 Competitive Landscape: Sustained Release Technology
9.1 Depomed, Inc.
9.1.1 Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.2 Coating Place, Inc.
9.2.1 Company overview
9.2.2 Product benchmarking
9.3 Corium International, Inc.
9.3.1 Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.4 Orbis Biosciences, Inc.
9.4.1 Company overview
9.4.2 Product benchmarking
9.5 Capsugel
9.5.1 Company overview
9.5.2 Product benchmarking
9.5.3 Strategic initiatives
9.6 Aradigm Corporation
9.6.1 Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.7 Alkermes plc
9.7.1 Company Overview
9.7.2 Financial Performance
9.7.3 Product Benchmarking
9.7.4 Strategic Initiatives

Chapter 10 Product Pipeline Analysis
10.1 Pipeline Development and Clinical Trials
10.1.1 Clinical Trials in Phase 4

List of Tables

Table 1 Factors used in segment share estimation
Table 2 List of secondary data sources
Table 3 List of Major Excipients Used in Sustained Release Formulations
Table 4 North America sustained release excipients market, by country, 2015 - 2026 (USD Million)
Table 5 North America sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 6 North America sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 7 North America sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 8 U.S. sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 9 U.S. sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 10 U.S. sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 11 Canada sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 12 Canada sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 13 Canada sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 14 Europe sustained release excipients market, by country, 2015 - 2026 (USD Million)
Table 15 Europe sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 16 Europe sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 17 Europe sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 18 Germany sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 19 Germany sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 20 Germany sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 21 U.K. sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 22 U.K. sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 23 U.K. sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 24 Asia Pacific sustained release excipients market, by country, 2015 - 2026 (USD Million)
Table 25 Asia Pacific sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 26 Asia Pacific sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 27 Asia Pacific sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 28 Japan sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 29 Japan sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 30 Japan sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 31 China sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 32 China sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 33 China sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 34 India sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 35 India sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 36 India sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 37 Latin America sustained release excipients market, by country, 2015 - 2026 (USD Million)
Table 38 Latin America sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 39 Latin America sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 40 Latin America sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 41 Brazil sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 42 Brazil sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 43 Brazil sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 44 Mexico sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 45 Mexico sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 46 Mexico sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 47 MEA sustained release excipients market, by country, 2015 - 2026 (USD Million)
Table 48 MEA sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 49 MEA sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 50 MEA sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 51 South Africa sustained release excipients market, by product, 2015 - 2026 (USD Million)
Table 52 South Africa sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
Table 53 South Africa sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Table 54 Clinical Trials in Phase 4

List of Figures

FIG. 1 Primary interviews, by sources
FIG. 2 Primary interviews, by region
FIG. 3 Market summary
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 Market restraint relevance analysis (Current & future impact)
FIG. 8 Key opportunities prioritized, by product
FIG. 9 Key opportunities prioritized, by route of administration
FIG. 10 Key opportunities prioritized, by technology
FIG. 11 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 12 Porter’s Five Forces Analysis
FIG. 13 Sustained release excipients market, product outlook: Key takeaways
FIG. 14 Sustained release excipients market: Product movement analysis
FIG. 15 Gelatin market, 2015 - 2026 (USD Million)
FIG. 16 Polymers market, 2015 - 2026 (USD Million)
FIG. 17 Minerals market, 2015 - 2026 (USD Million)
FIG. 18 Sugars market, 2015 - 2026 (USD Million)
FIG. 19 Alcohol market, 2015 - 2026 (USD Million)
FIG. 20 Chitosan market, 2015 - 2026 (USD Million)
FIG. 21 Sustained release excipients market, route of administration outlook: Key takeaways
FIG. 22 Sustained release excipients market: Route of administration movement analysis
FIG. 23 Oral market, 2015 - 2026 (USD Million)
FIG. 24 Intramuscular market, 2015 - 2026 (USD Million)
FIG. 25 Subcutaneous market, 2015 - 2026 (USD Million)
FIG. 26 Transdermal market, 2015 - 2026 (USD Million)
FIG. 27 Vaginal market, 2015 - 2026 (USD Million)
FIG. 28 Ophthalmic market, 2015 - 2026 (USD Million)
FIG. 29 Intravenous market, 2015 - 2026 (USD Million)
FIG. 30 Others market, 2015 - 2026 (USD Million)
FIG. 31 Sustained release excipients market, technology outlook: Key takeaways
FIG. 32 Sustained release excipients market: Technology movement analysis
FIG. 33 Targeted delivery market, 2015 - 2026 (USD Million)
FIG. 34 Micro encapsulation market, 2015 - 2026 (USD Million)
FIG. 35 Wurster technique market, 2015 - 2026 (USD Million)
FIG. 36 Transdermal market, 2015 - 2026 (USD Million)
FIG. 37 Implants market, 2015 - 2026 (USD Million)
FIG. 38 Coacervation market, 2015 - 2026 (USD Million)
FIG. 39 Others market, 2015 - 2026 (USD Million)
FIG. 40 Regional market place: Key takeaways
FIG. 41 Regional outlook, 2017 & 2026

Note: Product cover images may vary from those shown
3 of 4
  • Alkermes plc
  • Allergan plc
  • Aradigm Corporation
  • AstraZeneca
  • Capsugel
  • Coating Place, Inc.
  • Corium International, Inc.
  • Depomed, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Mayne Pharma Group Limited
  • Mylan N.V.
  • Novartis AG
  • Orbis Biosciences, Inc.
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll